Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalCCEL -3.73%61 3-Year Share Buyback Ratio is 1.80 as of May. 2026. GuruFocus rates CCEL with a GF Score™ of 61/100 and a GF Value™ of $5.43 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 446 Healthcare Providers & Services companies, Cryo-Cell International ranks better than 92.15% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Cryo-Cell International's current 3-Year Share Buyback Ratio was 1.80%.
The historical rank and industry rank for Cryo-Cell International's 3-Year Share Buyback Ratio or its related term are showing as below:
CCEL'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -12.3 Med: -0.3 Max: 14.2
Current: 1.8
During the past 13 years, Cryo-Cell International's highest 3-Year Share Buyback Ratio was 14.20%. The lowest was -12.30%. And the median was -0.30%.
CCEL's 3-Year Share Buyback Ratio is ranked better than 92.15% of 446
companies
in the Healthcare Providers & Services industry
Industry Median: -1.75
vs CCEL: 1.80
Cryo-Cell International (AMEX:CCEL) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Cryo-Cell International 3-Year Share Buyback Ratio Related Terms
CCEL vs EHSI, PIII, CCM: 3-Year Share Buyback Ratio Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International 3-Year Share Buyback Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's 3-Year Share Buyback Ratio falls into.
Cryo-Cell International 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 1.80 mean?
Cryo-Cell International (CCEL) has a 3-Year Share Buyback Ratio of 1.80 as of May. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cryo-Cell International and its competitors. According to the industry distribution chart, Cryo-Cell International ranks #35 out of 446 companies in the Healthcare Providers & Services industry, placing it in the top 7.8%.
Is Cryo-Cell International's 3-Year Share Buyback Ratio too high?
Cryo-Cell International's current 3-Year Share Buyback Ratio is 1.80. Based on the distribution chart, Cryo-Cell International ranks #35 out of 446 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cryo-Cell International has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's 3-Year Share Buyback Ratio compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #35 out of 446 companies for 3-Year Share Buyback Ratio. This places Cryo-Cell International in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Healthcare Providers & Services company?
A good 3-Year Share Buyback Ratio depends on the Healthcare Providers & Services industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cryo-Cell International and its competitors. Cryo-Cell International's current 3-Year Share Buyback Ratio is 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (CCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.43, compared to a current price of $4.39 — trading 19.2% below its estimated fair value. The current 3-Year Share Buyback Ratio is 1.80. Cryo-Cell International's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Cryo-Cell International (CCEL), the current 3-Year Share Buyback Ratio is 1.80 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (CCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of $4.39 is trading 19.2% below its estimated GF Value™ of $5.43.
GuruFocus considers Cryo-Cell International to be Modestly Undervalued.
Key valuation signals for CCEL:
3-Year Share Buyback Ratio: 1.80
GF Value™: $5.43 vs. price of $4.39 (19.2% below fair value)
No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
61GF Score
Get the complete analysis for CCEL
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCEL has been successfully added to your 
